InvestorsHub Logo
Followers 16
Posts 1898
Boards Moderated 0
Alias Born 05/12/2016

Re: None

Monday, 04/15/2019 7:02:12 AM

Monday, April 15, 2019 7:02:12 AM

Post# of 140476
Lots of chatter about concerns with launching with Hyst only... both in regard to sales potential and company value.

Please consider that a system that has ONE indication - lung biopsy - just sold for billions of dollars. That's enough to make a lot of investors happy, if we went for the same price as Auris (personally, I want more and think Titan is worth more).

This alone should address concerns about both issues, but we also have a predicate device showing how easily our technology will expand to a plethora of additional indications, and any organization interested in buying a robotic surgical system will be keenly aware of this.

I know, the counter-argument will be that we don't have FDA approval... Not worried about that either; the schedule is known; they are working closely with the FDA to prevent any surprises, and the predicate device will help ensure smooth sailing to approval. And I'm not expecting Titan to be sold next week; we can wait for approval.

No worries!